NL-OMON44954已完成2 期
The REDUCE FMR Trial: Safety and Efficacy of the CARILLON Mitral Contour System in Reducing Functional Mitral Regurgitation (FMR) associated with heart failure. - The REDUCE FMR Trial
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 5
研究概览
简要总结
Trial is onging in other countries
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •For Main study :;1. Diagnosis of dilated ischemic or non-ischemic cardiomyopathy
- •2. Functional Mitral Regurgitation: - 2+ (Moderate), 3+ (Moderate/Severe), or 4+ (Severe)
- •3. NYHA II, III, or IV (refer to Appendix D for NYHA Classification)
- •4. Six Minute Walk distance of at least 150 meters and no farther than 450 meters
- •5. Subject meets anatomic screening criteria as determined by angiographic screening at the time of the index procedure to ensure that implant can be sized and placed in accordance with the Instructions for Use
- •6. Left Ventricular Ejection Fraction <= 50%
- •NOTE: Subjects with LVEF of 41- 50% can only be included if baseline
- •NYHA is class III/IV AND MR grade is 3+/4+ (moderately-severe/severe)
- •7. LV end diastolic dimension (LVEDD) >55mm or LVEDD/BSA >3.0cm/m2
- •8. Stable heart failure medication regimen for at least three (3) months (refer to Appendix G for definition of stable heart failure regimen)
- •9. Age >= 18 years old and <= 85 years old
- •10. The subject has read the informed consent, agrees to comply with the requirements, and has signed the informed consent to participate in the study
- •11. Female subjects of child-bearing potential must have a negative serum βHCG test;For Cross-Over registry :
- •1. Diagnosis of dilated ischemic or non-ischemic cardiomyopathy
- •2. Functional Mitral Regurgitation: - 2+ (Moderate), 3+ (Moderate/Severe), or 4+ (Severe)
- •3. NYHA II, III, or IV (refer to Appendix D for NYHA Classification)
- •4. Subject meets anatomic screening criteria as determined by angiographic screening at the time of the index procedure to ensure that implant can be sized and placed in accordance with the Instructions for Use
- •5. Left Ventricular Ejection Fraction <= 50%
- •NOTE: Subjects with LVEF of 41- 50% can only be included if baseline
- •NYHA is class III/IV AND MR grade is 3+/4+ (moderately-severe/severe)
- •6. LV end diastolic dimension (LVEDD) >55mm or LVEDD/BSA >3.0cm/m2
- •7. The subject has read the informed consent, agrees to comply with the requirements, and has signed the informed consent to participate in the study
- •8. Female subjects of child-bearing potential must have a negative serum βHCG test
排除标准
- •Main study :
- •1. Hospitalization in past three (3) months due to myocardial infarction, coronary artery bypass graft surgery, and/or unstable angina
- •2. Hospitalization in the past 30 days for coronary angioplasty or stent placement
- •3. Subjects expected to require any cardiac surgery, including surgery for coronary artery disease (unprotected left main stenosis greater than or equal to 50% or, greater than or equal to 70% stenosis in at least three (3) epicardial coronary arteries in the absence of prior bypass surgery), or for pulmonic, aortic, or tricuspid valve disease within one (1) year
- •4. Subjects with echocardiographic documentation of non-compaction cardiomyopathy with associated hypercontractility of the cardiac structures supporting the mitral annulus
- •5. Subjects expected to require any percutaneous coronary intervention within 30 days of enrollment
- •6. Recipient of intravenous positive-inotrope infusion or intra- aortic balloon pump support within the past 30 days
- •7. Presence of a mechanical mitral heart valve, mitral bio-prosthetic valve or mitral annuloplasty ring
- •8. Pre-existing device (e.g., pacing lead) in coronary sinus (CS) / great cardiac vein (GCV), or anticipated need for cardiac resynchronization therapy (CRT) within twelve (12) months
- •9. Presence of a coronary artery stent under the CS / GCV in the implant target zone
- •10. Significant organic mitral valve pathology (e.g., moderate or severe myxomatous degeneration, with or without mitral leaflet prolapse, rheumatic disease, full or partial chordal rupture)
- •11. Presence of severe mitral annular calcification
- •12. Presence of left atrial appendage (LAA) clot. Patients with a current/ongoing (documented within the last 12 months) history of atrial fibrillation must undergo a trans-esophageal echo prior to the procedure to rule-out left atrial appendage clot to minimize the risk of thromboembolism
- •caused by the tissue plication
- •13. Cerebral vascular event within the past three (3) months
- •14. Presence of primary renal dysfunction or significantly compromised renal function as reflected by a serum creatinine > 2.2 mg/dL (194.5 µmol/L) OR estimated Glomerular Filtration Rate (eGFR) < 30 ml/min
- •15. Allergy to contrast dye that cannot be pre-medicated
- •16. Inability to undertake a six-minute walk test due to physical restrictions/limitations
- •17. Chronic severe pathology limiting survival to less than 12-months
- •18. Anticipated need of left ventricular assist device within twelve (12) months
- •19. Currently participating in an investigational study that clinically interferes
- •with the current study endpoints.;Cross-over registry:
- •1. Hospitalization in past three (3) months due to myocardial infarction, coronary artery bypass graft surgery, and/or unstable angina
- •2. Hospitalization in the past 30 days for coronary angioplasty or stent placement
- •3. Subjects with echocardiographic documentation of non-compaction cardiomyopathy with associated hypercontractility of the cardiac structures supporting the mitral annulus
- •4. Subjects expected to require any percutaneous coronary intervention within 30 days of enrollment
- •5. Recipient of intravenous positive-inotrope infusion or intra- aortic balloon pump support within the past 30 days
- •6. Presence of a mechanical mitral heart valve, mitral bio-prosthetic valve or mitral annuloplasty ring
- •7. Pre-existing device (e.g., pacing lead)
研究者
相似试验
已完成
3 期
Prospective multicenter clinical trial with the PRECIZION Presbyopic multifocal intraocular lens10047518CataractPresbyopiaNL-OMON41971OPHTEC BV10
已完成
不适用
Clinical Study to Evaluate the Safety and Performance of MANTA Vascular Closure DeviceAandoeningen aan de hartklepCardiac diseaseVascular intervention1001928010003184NL-OMON42594Essential Medical Inc.35
已完成
不适用
A randomised controlled trial to evaluate the effect of gloves containing silver fibre on burden caused by Raynaud's phenomenon in patients with systemic sclerosisRaynauds phenomenon10003816sclerodermaNL-OMON55595eids Universitair Medisch Centrum85
已完成
4 期
A prospective randomised controlled multicentre trial comparing half-dose photodynamic therapy (PDT) with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (CSC).Chronic central serous chorioretinopathy10047060NL-OMON39842niversitair Medisch Centrum119
已完成
3 期
A Multicenter Randomized Controlled Trial to Compare the Efficacy of End-ischemic Dual Hypothermic Oxygenated Perfusion with Standard Static Cold Storage of Liver Grafts Donated after Circulatory Death in Preventing Non-anastomotic Biliary Strictures after TransplantatioEnd-stage liver disease100179431001965410019818NL-OMON47263niversitair Medisch Centrum Groningen120